Results 1 - 10 of 46
Results 1 - 10 of 46. Search took: 0.015 seconds
|Sort by: date | relevance|
[en] The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC) treated with radiotherapy (RT) with or without chemotherapy at 10 institutions in the Tokai District, Japan. Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplete cases due to issues such as discontinuation, using the method of Kaplan-Meier and compared using the log-rank test. Results were considered statistically significant at the level of p < 0.05. For 122 patients, the tumors were classified as T1a, while 64 patients had T1b tumors, and 84 patients had T2 tumors. In three cases of T1 tumors, the subtype was unknown. Combined chemoradiotherapy (CRT) was administered during each stage, and various chemotherapy drugs and regimens were used. The median follow-up period was 55.4 months. The 5-year LC rates for T1a, Tb, and T2 tumors in all patients were 87.9%, 82.7%, and 74.1%, respectively. The difference between T1a and T2 was statistically significant (p = 0.016). The 5-year LC rates for T1a, Tb, and T2 with CRT were 92.7%, 78.6%, and 80.7%, respectively, while the rates with radiation alone were 86.5%, 83.8%, and 64.4%, respectively. The difference between CRT and RT alone was not statistically significant in each stage. In this survey, CRT was performed for early GC at most institutions in clinical practice. Our data showed no statistical difference in the LC rates between CRT and RT alone in each stage. However, there was a tendency for the LCRs of the CRT group to be more favorable than those of the RT group in the T2-stage
[en] High-risk human papillomavirus type 16 (HPV16) is a risk factor for cervical cancer. Previous studies suggest that polymorphisms in the E6 gene or the long control region(LCR)of HPV16 may alter the oncogenic potential of the virus. The aims of this study were to investigate the genetic variations of HPV16 E6 gene and LCR in isolates from Chinese population and correlation of the E6 and LCR polymorphisms with disease status of infected patients. HPV16 positive endocervical specimens were collected from 304 women living in Northeast of China. Sequences of E6 gene and LCR were analyzed by PCR-sequencing. Two lineages were found in the populations, including EUR lineage and As lineage. Based on the HPV16 prototype, the most frequent variation in the E6 gene was T178A/G (48.7%), followed by mutations of G94A (12.2%) and T350G (9.9%). The rank orders of incidence of E6 variations in amino acid were as follows: D25E (46.3%), L83V (9.9%) and H78Y (4.3%). Nucleotide variations in LCR were found in all the 304 isolates from HPV16 positive cervical samples. The most commonly observed LCR variations were the transition replacement G7193T, 7434CIns, G7521A and 7863ADel (100%). The As lineage was associated with HPV persistent infections and with disease status of ≥CIN2,3. The EUR lineage variants showed a negative trend of association with the severity of ≥CIN2,3. Among 41 variations found in LCR, 25 (61.0%) were located at the binding sites for transcription factors. Occurrence of ≥CIN2,3 was significantly associated with the mutations of R10G/L83V in E6 and the C7294T co-variation in LCR, after adjusting for ages of infected patients. Associations between As lineage and HPV persistent infections, and with disease status of ≥CIN2,3, and an association between the EUR lineage and negative trend of association with the severity of ≥CIN2,3 were found in this study. An association between a co-variation of R10G/L83V in E6 and C7294T in LCR and an increased risk for developing CIN-2,3 was found in a HPV16 infected population of Chinese women. These findings indicate that HPV16 polymorphism influences development of CIN-2,3
[en] Within this publication a detailed overview about the national and international solal't1lel1nai standards is made. The various tests are described and a cross reference list for comparing the different standards is given. Moreover a certification model is presented and the advantage of third party assessment is carried out. The requirement for a solar thermal test laboratory to conduct independent third party assessment by means of an ISO/IEC17065 accreditation is given. Finally the concept of a quality system for solar thermal markets is explained and major advantages are outlined. Solar thermal systems and their components are described in various national and international standards. In Europe the standard EN12975 defines the regulations and requirements for solar thermal collectors. The standard EN12976 is established for the evaluation of factory made solar thermal systems. The EN12977 is the state of the art standard for the evaluation of custom build systems. Nowadays in Libya the standard ISO9806 for solar collectors and the standard ISO9459 for domestic water heating systems define the regulations and requirements for solar thermal collectors and systems. In the meanwhile, empowered Center for Renewable Energy and Energy Efficiency Certification Body is under construction. This body is working now to set the minimum requirements of the testing facilities of solar thermal systems. The international standard for collector testing is the ISO9806 and the standard ISO9459 Part 2, 4, 5 for domestic water heating systems. Within the year 2013 a revision of the ISO9806 will be published and, for the first time, a consistent harmonized standard for the main solar thermal markets will be set in force. Besides the various standards for solar thermal products a meaningful element for the quality assurance and the customer protection is third party certification. Third party certification involves an independent assessment, declaring that specified requirements regarding a product are fulfilled. In a certification process based on specified certification rules an authorized certification body is confirming that a solar thermal product has passed performance tests, reliability tests and further requirements according to the standards. In Europe a certification body holds an accreditation according to EN45011. At international level the standard ISO/IEC17065 is in force. Test results as a basis for product certification are determined by solar thermal test laboratories. The implementation and the business operation of such a solar thermal test laboratory is an important element within the national/regional solar thermal market. To ensure the quality of the products and to attend the role of an observer on the market, the test facility has to fulfill a number of requirements. Besides the necessary technical equipment and the implementation of tests in accordance with the various national and international standards, the laboratory shall realize a quality management system to guarantee the quality of tests and services. Based on the technical equipment, the testing scope and an implemented Quality Management System (QMS), the test laboratory can achieve an accreditation according to ISO/IEC17025 as basis for independent third party testing. Independent testing and evaluation of solar thermal collectors and components like hot water stores and controllers offers an important medium for quality assurance. To guarantee a high degree of product quality and consumer protection a quality system for the solar thermal market is necessary. Core of the quality assurance of a functioning solar thermal market are the national standards body, which is developing standards and regulations as a working basis ill technical committees, the national metrology institute that guarantees the traceability of measurements on fundamental and natural constants, and finally the national accreditation body which ensures the conformity of the various actors to a specific standard. Laboratories work closely with the certification authorities and apply the developed specific norms and standards. The certification bodies must ensure the conformance of their test laboratories with the standard ISO/IEC17025, which include the quality standard ISO 9001:2008 and also include additional requirements. The traceability of the metrics of solar thermal testing laboratories is usually made with the help of calibration laboratories that are specialized on certain measurements. Those are also accredited and ensure the traceability of their measurements to the national meteorology institute. Other stake holders are the group of importers and exporters and foreign investors who are on the national market in entrepreneurial activities, as well as the group of consumer organizations that represent the interests of customers. By means of good networking of stake holders and focusing 011 the quality process, a high-quality and flourishing solar thermal market can be created.(author)
[en] Human papillomaviruses (HPVs) replicate as nuclear plasmids in infected cells. Since the DNA replication machinery is generally conserved between humans and Saccharomyces cerevisiae, we studied whether HPV-1 DNA can replicate in yeast. Plasmids containing a selectable marker (with or without a yeast centromere) and either the full-length HPV-1 genome or various regions of the viral long control region (LCR) and the 3' end of the L1 gene were introduced into S. cerevisiae and their ability to replicate episomally was investigated. Our results show that HPV-1 sequences promote episomal replication of plasmids although the yeast centromere is required for plasmid retention. We have mapped the autonomously replicating sequence activity of HPV-1 DNA to a 450 base-pair sequence (HPV-1 nt 6783-7232) that includes 293 nucleotides from the 5' region of the viral LCR and 157 nucleotides from the 3' end of the L1 gene. The HPV-1 ARS does not include the binding sites for the viral E1 and E2 proteins, and these proteins are dispensable for replication in S. cerevisiae
[en] This paper deals with the electromagnetic field interact in biological tissues. It is actually one of the important challenges for the electromagnetic field for the recent years. The experimental techniques are use in Broad-band Dielectric Measurement (BDM) with LCR meters. The authors used Bones and scales of Fish taken from Narmada River (Rajghat Dist. Barwani) as biological tissues. Experimental work carried out done in inter-university consortium (IUC) Indore. The major difficulties that appear are related to the material properties, to the effect of the electromagnetic problem and to the thermal model of the biological tissues.
[en] Purpose: To performed a systematic review and pooled analysis to compare clinical outcomes of stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) for the treatment of medically inoperable stage I non-small cell lung cancer. Methods and Materials: A comprehensive literature search for published trials from 2001 to 2012 was undertaken. Pooled analyses were performed to obtain overall survival (OS) and local tumor control rates (LCRs) and adverse events. Regression analysis was conducted considering each study's proportions of stage IA and age. Results: Thirty-one studies on SBRT (2767 patients) and 13 studies on RFA (328 patients) were eligible. The LCR (95% confidence interval) at 1, 2, 3, and 5 years for RFA was 77% (70%-85%), 48% (37%-58%), 55% (47%-62%), and 42% (30%-54%) respectively, which was significantly lower than that for SBRT: 97% (96%-98%), 92% (91%-94%), 88% (86%-90%), and 86% (85%-88%) (P<.001). These differences remained significant after correcting for stage IA and age (P<.001 at 1 year, 2 years, and 3 years; P=.04 at 5 years). The effect of RFA was not different from that of SBRT on OS (P>.05). The most frequent complication of RFA was pneumothorax, occurring in 31% of patients, whereas that for SBRT (grade ≥3) was radiation pneumonitis, occurring in 2% of patients. Conclusions: Compared with RFA, SBRT seems to have a higher LCR but similar OS. More studies with larger sample sizes are warranted to validate such findings.
[en] A two dimensional nonautonomous dissipative forced series LCR circuit with a simple nonlinear element exhibiting an immense variety of dynamical features is proposed for the first time. Unlike the usual cases of nonlinear element, the nonlinear element used here possesses three segment piecewise linear character with one positive and one negative slope. This nonlinearity is verified to be sufficient to produce chaos with high complexity in many established nonautonomous nonlinear circuits, such as MLC, MLCV, driven Chua, etc., thus indicating an universal behavior similar to the familiar Chua's diode. The dynamics of the proposed circuit is studied experimentally, confirmed numerically, simulated through PSPICE and proved mathematically. An important feature of the circuit is its ability to show dual chaotic behavior.
[en] Stereotactic body radiotherapy (SBRT) is a relatively new treatment for liver tumor. The outcomes of SBRT for liver tumor unfit for ablation and surgical resection were evaluated. Liver tumor patients treated with SBRT in seven Japanese institutions were studied retrospectively. Patients given SBRT for liver tumor between 2004 and 2012 were collected. Patients treated with SBRT preceded by trans-arterial chemoembolization (TACE) were eligible. Seventy-nine patients with hepatocellular carcinoma (HCC) and 51 patients with metastatic liver tumor were collected. The median biologically effective dose (BED) (α/β = 10 Gy) was 96.3 Gy for patients with HCC and 105.6 Gy with metastatic liver tumor. The median follow-up time was 475.5 days in patients with HCC and 212.5 days with metastatic liver tumor. The 2-year local control rate (LCR) for HCC and metastatic liver tumor was 74.8% ± 6.3% and 64.2 ± 9.5% (p = 0.44). The LCR was not different between BED_1_0 ≥ 100 Gy and < 100 Gy (p = 0.61). The LCR was significantly different between maximum tumor diameter > 30 mm vs. ≤ 30 mm (64% vs. 85%, p = 0.040) in all 130 patients. No grade 3 laboratory toxicities in the acute, sub-acute and chronic phases were observed. There was no difference in local control after SBRT in the range of median BED_1_0 around 100 Gy for between HCC and metastatic liver tumor. SBRT is safe and might be an alternative method to resection and ablation. There was no difference in local control after SBRT in the range of median BED_1_0 around 100 Gy for between HCC and metastatic liver tumor and SBRT is safe and might be an alternative method to resection and ablation
[en] Despite intensive multimodal treatment, outcome of patients with malignant glioma remains poor, and a standard dose of radiotherapy for anaplastic astrocytoma has not been defined. In the past RTOG study (83-02), the arm of 72 Gy hyperfractionated radiotherapy (HFRT) for malignant gliomas showed better outcome than the arms of higher doses (76.8 – 81.6 Gy) and the arms of lower doses (48 – 54.4 Gy). The purpose of this study is to verify the efficacy of this protocol. From July 1995, 44 consecutive eligible patients with histologically proven anaplastic astrocytoma were enrolled in this study (HFRT group). The standard regimen in this protocol was post-operative radiotherapy of 72 Gy in 60 fractions (1.2 Gy/fraction, 2 fractions/day) with concurrent chemotherapy (weekly ACNU). The primary endpoint was local control rate (LCR), and the secondary endpoints were overall survival (OS), progression-free survival (PFS) and late toxicity. Three-year OS of the HFRT group was 64.8% (95% confidence interval; 48.4–81.3%). Three-year PFS rate and LCR were 64.4% (95%CI: 48.4–80.3%) and 81.6% (95%CI: 69.2–94.8%), respectively. The number of failures at 5 years in the HFRT group were 14 (32%). The number of failures inside the irradiation field was only about half (50%) of all failures. One (2%) of the patients clinically diagnosed as brain necrosis due to radiation therapy. The results of this study suggested that 72 Gy HFRT seemed to show favorable outcome for patients with anaplastic astrocytoma with tolerable toxicity
[en] Locally recurrent non-small cell lung cancer (NSCLC) poses a great challenge to physicians. This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. Fifty two patients with locally recurrent stage III NSCLC after concurrent chemoradiotherapy were randomly divided into two groups (n = 26). The patients in experimental group were treated with implantation of radioactive "1"2"5I seeds and DP regimen (docetaxel 60 mg/m"2/cisplatin 75 mg/m"2). Patients in control group received DP chemotherapy. The local control rate (LCR), progression-free survival (PFS), and overall response rate (ORR) were defined according to the Response Evaluation Criteria in Solid Tumors (RECIST). With a median follow-up time of 11 months, PFS and LCR was 8 months (95 % CI: 6.99–9.01 months) vs. 5.5 months (95 % CI: 4.43–6.57 months) (P < 0.05) and 10 months (95 % CI: 8.72–11.28 months) vs. 6.2 months (95 % CI: 5.27–7.13 months) (P < 0.05) in the experimental and control groups, respectively. The ORR did not differ between treatment groups and was noted to be 69.2 % and 57.7 %, respectively (P >0.05). There was no occurrence of severe complications in experimental and control groups. The combination of "1"2"5I brachytherapy and second-line chemotherapy is superior to chemotherapy alone and is an effective and safe therapy for this disease